MIT Sloan School of Management

ibex Names Taylor C. Greenwald Chief Financial Officer

Retrieved on: 
Thursday, August 3, 2023
Treasury, Interim, Georgia Tech, Endurance International Group, Controller, Culture, Convergys, MBA, Customer experience, Accounting, MIT Sloan School of Management, Corporate services, Engineering, BPO, Ibex, Massachusetts Institute of Technology, Management

WASHINGTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- ibex (NASDAQ: IBEX), a leading global provider of business process outsourcing (BPO) and customer engagement technology solutions, today announced that Taylor C. Greenwald has been appointed Chief Financial Officer, effective August 14, 2023.

Key Points: 
  • WASHINGTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- ibex (NASDAQ: IBEX), a leading global provider of business process outsourcing (BPO) and customer engagement technology solutions, today announced that Taylor C. Greenwald has been appointed Chief Financial Officer, effective August 14, 2023.
  • He joins ibex from Synchronoss Technologies where he served as Executive Vice President and Chief Financial Officer.
  • Previously, Greenwald was Senior Vice President Finance and Chief Financial Officer, Web Presence for Endurance International Group, an IT services company.
  • Michael Darwal, who served as Interim Chief Financial Officer for the Company since July 1, will remain as Executive Vice President of Investor Relations and Deputy Chief Financial Officer, reporting to Greenwald.

John Krafcik Joins Rivian’s Board of Directors

Retrieved on: 
Wednesday, August 2, 2023
Automotive Manufacturing, Aftermarket, EV, Electric Vehicles, Automotive, Manufacturing, General Automotive, Alternative Vehicles, Fuels, Alternative Energy, Environment, Energy, Sustainability, MIT Sloan School of Management, Stanford University, Hyundai Motor America, Mechanical engineering, Automotive industry, John Krafcik, Ford Motor Company, Supervisory board, RJ, Toyota, Program on Vehicle and Mobility Innovation, Hyundai, GM, Engineering, NUMMI, R. J. Scaringe, Transport, TrueCar, Management, Waymo, Rivian

Rivian Automotive, Inc. (NASDAQ: RIVN) announced today that John Krafcik has been named to its board of directors.

Key Points: 
  • Rivian Automotive, Inc. (NASDAQ: RIVN) announced today that John Krafcik has been named to its board of directors.
  • “We are thrilled to welcome John to the Rivian board,” said RJ Scaringe, Founder and CEO of Rivian.
  • “John has tremendous leadership experience in the automotive industry and an impressive track record of building and leading innovative companies.
  • Before that, Krafcik served as President and CEO of Hyundai Motor America, where he led the transformation of the brand.

MGM RESORTS APPOINTS DANIEL YANG CHIEF CUSTOMER & INNOVATION OFFICER

Retrieved on: 
Thursday, July 27, 2023
Yang, MIT Sloan School of Management, MGM, Viacom, MGM Resorts International, University, Aristocrat Leisure, Marketing, Berkeley, Booz Allen Hamilton, MBA, Digital technology, Growth, Chief innovation officer, NYSE, Management, Paramount

LAS VEGAS, July 27, 2023 /PRNewswire/ -- MGM Resorts International (NYSE: MGM) announced today the appointment of Daniel Yang as Chief Customer & Innovation Officer.

Key Points: 
  • LAS VEGAS, July 27, 2023 /PRNewswire/ -- MGM Resorts International (NYSE: MGM) announced today the appointment of Daniel Yang as Chief Customer & Innovation Officer.
  • Yang joins MGM Resorts from Aristocrat Leisure Limited where he served as the company's Chief Strategy Officer responsible for driving corporate strategy, long-range planning, and corporate development.
  • "I'm thrilled to be joining MGM Resorts as the company continues to accelerate its plan to create and deploy high impact digital products and services supporting the customer experience in multiple channels," said Yang.
  • "The company and its leaders are driven to position MGM Resorts as the world's premier gaming entertainment company, and the destination of choice for all their customer segments.

Supply Change Capital Closes Debut $40M Fund to Invest in the Future of Food

Retrieved on: 
Monday, July 24, 2023
Samsung Catalyst Fund, Male, Food, Female, Boeing, Investment, Food industry, Culture, Agriculture, Like a Boss (film), Cadena, Strategic Innovation Fund, MIT, INC, Pulse, Illinois Treasurer, Biodiversity, Bank of America, MIT Sloan School of Management, Water, General Mills, Atmosphere, Diversity, JPMorgan Chase, Climate, Bank, Health, Corporate title, Cryptocurrency, Renewable energy, Mars, Supply

LOS ANGELES, July 24, 2023 /PRNewswire/ -- Supply Change Capital, a venture capital firm that invests in the future of food, today announced the close of its inaugural $40M Fund. One of the largest Latina-led funds, the firm has deployed over $13 million across 15 early-stage food and agriculture technology companies since June 2021. Investments include deep tech food, agriculture and ingredient companies, supply chain technology, and enterprise software. Latinx, Black, and/or Female Founder/CEOs comprise 80% of the portfolio.

Key Points: 
  • LOS ANGELES, July 24, 2023 /PRNewswire/ -- Supply Change Capital, a venture capital firm that invests in the future of food, today announced the close of its inaugural $40M Fund.
  • Supply Change Capital, a venture capital firm investing in the future of food, announced the close of its $40M Fund I.
  • "Supply Change Capital represents the future of food and the venture industry," said Johnny Tran, managing director, 301 INC, the venture capital arm of General Mills.
  • Supply Change Capital is female and Latina-owned, a rarity in the world of venture capital.

SGH Appoints Mary G. Puma as Independent Member of Board of Directors

Retrieved on: 
Wednesday, July 19, 2023
Software, Networks, Hardware, Electronic Design Automation, Technology, Semiconductor, Other Technology, Security, Tufts University, MIT Sloan School of Management, General Electric, Marketing, SEMI, Multimedia, Nordson Corporation, Economics, Eaton Corporation, SMART, Puma, SGH, Management, Axcelis Technologies

SMART Global Holdings , Inc. (“SGH”) (Nasdaq: SGH ) today announced the appointment of Mary G. Puma to its board of directors, effective July 15, 2023.

Key Points: 
  • SMART Global Holdings , Inc. (“SGH”) (Nasdaq: SGH ) today announced the appointment of Mary G. Puma to its board of directors, effective July 15, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230719761897/en/
    SGH (SMART Global Holdings) today announced the appointment of Mary G. Puma to its board of directors, effective July 15, 2023.
  • (Photo: Business Wire)
    "We are excited to welcome Mary to our board,” said Mark Adams.
  • Puma has served as executive chairperson of the board at Axcelis since May 2023, and previously served as chairperson of the board from 2005 to 2015.

COUR Pharmaceuticals Appoints Dannielle Appelhans as Chief Operating Officer

Retrieved on: 
Wednesday, July 19, 2023
Rubius, University, Massachusetts Institute of Technology, Senior, Master of Science in Management, Value chain, Immune tolerance, Lead, Novartis Gene Therapies, MBA, Research, Myasthenia gravis, McKinsey & Company, Eli Lilly, Organization, MIT Sloan School of Management, Novartis, Patient, School, Immune system, Eli Lilly and Company, Engineering education, Therapy, Pharmaceutical industry, Management, Science, Engineering

CHICAGO, July 19, 2023 /PRNewswire/ -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles designed to reprogram the immune system, today announced the appointment of Dannielle Appelhans as Chief Operating Officer, effective immediately.

Key Points: 
  • CHICAGO, July 19, 2023 /PRNewswire/ -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles designed to reprogram the immune system, today announced the appointment of Dannielle Appelhans as Chief Operating Officer, effective immediately.
  • Ms. Appelhans served most recently as the Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded and clinical-phase biopharmaceutical company pioneering cellular medicines.
  • She previously served as its Chief Operating Officer, where she oversaw corporate strategy, communications, quality, technical development, and operations.
  • "COUR represents an ideal opportunity to apply my relevant skill-set at an important inflection point in the Company's evolution in bringing two promising, proprietary autoimmune programs to treat Myasthenia Gravis and type 1 diabetes into human proof-of-concept studies in the near-term," said Dannielle Appelhans, incoming Chief Operating Officer at COUR Pharmaceuticals.

Biotech and Biopharma Executive Eliana Clark Joins Culture Biosciences’ Advisory Board

Retrieved on: 
Wednesday, July 19, 2023
Tufts University, Process, The Advisory Board Company, University, Worcester Polytechnic Institute, Senior, Biogen, CMC, National Center for Manufacturing Sciences, Doctor of Philosophy, Advisory board, Quality, Greater Boston, National university, Patient, MIT Sloan School of Management, SAN, Culture, Therapy, Chemical engineering, Biochemical engineering, Management, Chemical substance, Intellia Therapeutics

SAN FRANCISCO, July 19, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences is excited to welcome Eliana Clark, PhD, Executive Vice President and Chief Technical Officer at Intellia Therapeutics, Inc., to the company’s Advisory Board.

Key Points: 
  • SAN FRANCISCO, July 19, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences is excited to welcome Eliana Clark, PhD, Executive Vice President and Chief Technical Officer at Intellia Therapeutics, Inc., to the company’s Advisory Board.
  • The group of seasoned industry leaders provides Culture’s leadership with insights and recommendations as the company establishes new partnerships and pursues new growth opportunities in biotech and biopharma.
  • “We are thrilled that Eliana lends her experience to help Culture drive innovation that can overcome persistent bottlenecks in upstream bioprocess development,” said Will Patrick, Chief Executive Officer of Culture Biosciences.
  • Eliana held post-doc roles in Biochemical Engineering at the University of Delaware and the Worcester Polytechnic Institute.

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

Retrieved on: 
Tuesday, July 11, 2023
Chem, Trinity College, DNA, PPD, MIT Sloan School of Management, Partnership, Biochemistry, Therapy, Doctor of Philosophy, Biotechnology, PPD, Inc., Trust, MBA, Partner (business rank), Trust Company, History, Messenger, Georgetown University, Chemistry, Foreign Service, Acquisition, Patient, ERNA, Brown University, Machine learning, School, Drug discovery, Walsh School of Foreign Service, Juno Therapeutics, Library, Technology transfer, Massachusetts Institute of Technology, Pharmaceutical industry, Management, Film industry, Fine chemical, Eterna

“We are delighted to welcome Brant and Richard to our Board.

Key Points: 
  • “We are delighted to welcome Brant and Richard to our Board.
  • Mr. Binder began his career in venture capital and private equity investment at Trust Company of the West.
  • Richard Wagner, Ph.D., is a biotechnology entrepreneur with more than 30 years of experience creating and managing drug discovery innovations.
  • Both Mr. Binder and Dr. Wagner served in executive operating roles and on the Board of Directors of the foregoing companies.

Iridia Announces Appointment of Buck Watia as Vice President, Corporate Development

Retrieved on: 
Tuesday, July 11, 2023
Cloud, Columbia Senior Executive Program, DNA, IPO, University, Marketing, Culture, Verisign, MIT Sloan School of Management, Microsoft, Metasploit, History, Strategy, Security, ArcSight, Bachelor of Business Administration, Business administration, Acquisition, SAN, Nanofluidic circuitry, Harvard Business School, Growth, AI, HP, Boise, Idaho, Boise State University, Corporate development, Management, Iridia

SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Iridia™ Inc., a pioneer in the field of DNA-based data storage, is excited to welcome Buck Watia as the Vice President of Corporate Development.

Key Points: 
  • SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Iridia™ Inc., a pioneer in the field of DNA-based data storage, is excited to welcome Buck Watia as the Vice President of Corporate Development.
  • With a demonstrated history of accelerating tech startups to success and launching impactful ventures within leading software, infrastructure, and Cloud companies, Buck is poised to drive significant transformation at Iridia.
  • Before joining Iridia, Buck held a key role as the Head of Strategy & Growth at Microsoft, within the Security, Cloud & AI business.
  • He led the business and corporate development functions at CyberX, guiding it towards a strategic acquisition by Microsoft in 2020.

Akamis Bio Strengthens Leadership Team with Key Executive Appointments

Retrieved on: 
Thursday, July 6, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Yale University, Mace Head Atmospheric Research Station, MIT Sloan School of Management, Business development, Novartis Institute for Tropical Diseases, Research strategies of election campaign communication research, Bluebird bio, Therapy, Biochemistry, Senior, University, Doctor of Philosophy, Bio, Feinberg School of Medicine, University of Hamburg, Business, Bayer, DRS, MBA, Biomedical Research, CMO, Genentech, MIT, Associate, Teaching hospital, PBMC, Harvard Medical School, Research and development, Multiple Myeloma Research Foundation, Takeda Oncology, University of Cologne, Patient, CBO, CD40, Hematology, Swarthmore College, Northwestern University, SQZ, Multiple myeloma, Pharmaceutical industry, Management, Research

as Chief Medical Officer (CMO), Peter Kosa, Ph.D. as Chief Business Officer (CBO), and Samantha Bailey-Bucktrout, Ph.D. as Senior Vice President, Head of Research.

Key Points: 
  • as Chief Medical Officer (CMO), Peter Kosa, Ph.D. as Chief Business Officer (CBO), and Samantha Bailey-Bucktrout, Ph.D. as Senior Vice President, Head of Research.
  • “As CMO, Oliver’s decades of experience in oncology drug development will be critical as we advance our lead program, NG-350A, toward clinical proof-of-concept studies.
  • Dr. Kosa has also held leadership positions at XOMA, Bayer Healthcare, and Connecticut Innovations.
  • She joined Akamis Bio from the Parker Institute for Cancer Immunotherapy in San Francisco where she was Senior Director of Research and Development.